Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 607 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 607 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total transaction of $27,242.16. Following the sale, the chief operating officer now directly owns 200,540 shares in the company, valued at $9,000,235.20. This represents a 0.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Jonathan Young also recently made the following trade(s):

• On Tuesday, March 4th, Jonathan Young sold 50,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.86, for a total value of $2,243,000.00.
• On Monday, February 3rd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $53.81, for a total value of $538,100.00.
• On Thursday, January 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.03, for a total value of $280,300.00.

Akero Therapeutics Trading Down 1.6 %

NASDAQ:AKRO opened at $44.15 on Monday. The business’s 50-day simple moving average is $42.10 and its 200-day simple moving average is $33.89. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The stock has a market capitalization of $3.52 billion, a PE ratio of -11.77 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Sell-side analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Citigroup increased their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Morgan Stanley reiterated an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. HC Wainwright upped their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, March 3rd. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, UBS Group increased their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $76.29.

Institutional Trading of Akero Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of AKRO. Wellington Management Group LLP boosted its position in shares of Akero Therapeutics by 54.4% during the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after buying an additional 2,782,029 shares during the period. Point72 Asset Management L.P. bought a new stake in Akero Therapeutics in the 3rd quarter valued at approximately $37,392,000. RTW Investments LP boosted its position in Akero Therapeutics by 15.9% during the 4th quarter. RTW Investments LP now owns 6,859,823 shares of the company’s stock worth $190,840,000 after acquiring an additional 940,388 shares during the last quarter. Deep Track Capital LP grew its stake in shares of Akero Therapeutics by 116.0% during the 4th quarter. Deep Track Capital LP now owns 1,490,000 shares of the company’s stock worth $41,452,000 after acquiring an additional 800,216 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Akero Therapeutics in the fourth quarter valued at approximately $18,059,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.